Short Tryptamine-Based Peptoids as Potential Therapeutics for Microbial Keratitis: Structure-Function Correlation Studies.

Staphylococcus aureus antimicrobial peptide antimicrobial resistance bacterial keratitis membrane disruption peptidomimetics peptoids

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
08 Aug 2022
Historique:
received: 18 07 2022
revised: 05 08 2022
accepted: 05 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Peptoids are peptidomimetics that have attracted considerable interest as a promising class of antimicrobials against multi-drug-resistant bacteria due to their resistance to proteolysis, bioavailability, and thermal stability compared to their corresponding peptides. Staphylococcus aureus is a significant contributor to infections worldwide and is a major pathogen in ocular infections (keratitis). S. aureus infections can be challenging to control and treat due to the development of multiple antibiotic resistance. This work describes short cationic peptoids with activity against S. aureus strains from keratitis. The peptoids were synthesized via acid amine-coupling between naphthyl-indole amine or naphthyl-phenyl amine with different amino acids to produce primary amines (series I), mono-guanidines (series II), tertiary amine salts (series III), quaternary ammonium salts (series IV), and di-guanidine (series V) peptoids. The antimicrobial activity of the peptoids was compared with ciprofloxacin, an antibiotic that is commonly used to treat keratitis. All new compounds were active against Staphylococcus aureus S.aureus 38. The most active compounds against S.aur38 were 20a and 22 with MIC = 3.9 μg mL−1 and 5.5 μg mL−1, respectively. The potency of these two active molecules was investigated against 12 S. aureus strains that were isolated from microbial keratitis. Compounds 20a and 22 were active against 12 strains with MIC = 3.2 μg mL−1 and 2.1 μg mL−1, respectively. There were two strains that were resistant to ciprofloxacin (Sa.111 and Sa.112) with MIC = 128 μg mL−1 and 256 μg mL−1, respectively. Compounds 12c and 13c were the most active against E. coli, with MIC > 12 μg mL−1. Cytoplasmic membrane permeability studies suggested that depolarization and disruption of the bacterial cell membrane could be a possible mechanism for antibacterial activity and the hemolysis studies toward horse red blood cells showed that the potent compounds are non-toxic at up to 50 μg mL−1.

Identifiants

pubmed: 36009943
pii: antibiotics11081074
doi: 10.3390/antibiotics11081074
pmc: PMC9404767
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Australian Research Council
ID : DP180100845

Références

JAMA Ophthalmol. 2020 May 1;138(5):439-450
pubmed: 32271355
PLoS One. 2019 Jul 29;14(7):e0215703
pubmed: 31356627
Chembiochem. 2010 Jul 5;11(10):1356-60
pubmed: 20503219
Biochemistry. 1974 Jul 30;13(16):3315-30
pubmed: 4842277
Front Microbiol. 2019 Apr 01;10:539
pubmed: 30988669
Bioorg Med Chem. 1999 Sep;7(9):1781-5
pubmed: 10530925
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9367-71
pubmed: 1409642
Pharmaceuticals (Basel). 2015 Jul 13;8(3):366-415
pubmed: 26184232
Biopolymers. 2019 Jun;110(6):e23274
pubmed: 30892696
Antimicrob Agents Chemother. 2015 Jul;59(7):4112-20
pubmed: 25941221
Biochim Biophys Acta. 2014 Oct;1838(10):2492-2502
pubmed: 24878450
Biochemistry. 1999 Jun 1;38(22):7235-42
pubmed: 10353835
Chem Rev. 2001 Oct;101(10):3219-32
pubmed: 11710070
Bioorg Med Chem Lett. 2003 Dec 15;13(24):4505-9
pubmed: 14643357
Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
Mol Divers. 1997;3(1):1-15
pubmed: 9527473
Prog Lipid Res. 2012 Apr;51(2):149-77
pubmed: 22245454
Am J Ophthalmol. 2019 Sep;205:74-81
pubmed: 30951687
Infect Genet Evol. 2019 Apr;69:203-210
pubmed: 30708134
BMC Ophthalmol. 2017 Aug 22;17(1):151
pubmed: 28830451
Ophthalmology. 2005 Mar;112(3):466-9
pubmed: 15745775
Clin Microbiol Rev. 2006 Jul;19(3):491-511
pubmed: 16847082
Clin Infect Dis. 2012 May;54(10):1381-7
pubmed: 22447793
Br J Ophthalmol. 2017 Feb;101(2):108-113
pubmed: 27130916
Drug Resist Updat. 2016 May;26:43-57
pubmed: 27180309
Molecules. 2012 Jul 02;17(7):7914-26
pubmed: 22751258
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):362-8
pubmed: 19684005
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Biopolymers. 2018 Jan;109(1):
pubmed: 29068055
J Med Chem. 2014 Feb 27;57(4):1428-36
pubmed: 24479371
J Am Chem Soc. 2013 Feb 20;135(7):2835-44
pubmed: 23343406
J Am Coll Cardiol. 2018 Dec 11;72(23 Pt B):2964-2979
pubmed: 30522631
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Antibiotics (Basel). 2021 Oct 03;10(10):
pubmed: 34680784
Bioorg Med Chem Lett. 2002 Apr 8;12(7):1035-8
pubmed: 11909711
Biopolymers. 1996 Jun;38(6):781-90
pubmed: 8652798
J Med Chem. 2011 Oct 27;54(20):7005-22
pubmed: 21848318
Curr Opin Chem Biol. 2002 Dec;6(6):872-7
pubmed: 12470744
Clin Ophthalmol. 2012;6:919-24
pubmed: 22791973
Sci Rep. 2017 Feb 14;7:42332
pubmed: 28195195
J Biol Chem. 2012 Mar 2;287(10):7738-45
pubmed: 22253439
Sci Rep. 2020 Sep 9;10(1):14805
pubmed: 32908179
Biochim Biophys Acta. 2016 May;1858(5):980-7
pubmed: 26514603
Chem Biol. 2007 Jun;14(6):671-7
pubmed: 17584614
Molecules. 2017 Aug 29;22(9):
pubmed: 28850098
Graefes Arch Clin Exp Ophthalmol. 2020 Aug;258(8):1745-1755
pubmed: 32358645
Biopolymers. 2013 Nov;100(6):572-83
pubmed: 23553602
Biopolymers. 2008;90(3):369-83
pubmed: 18098173
Biochemistry. 2017 Mar 21;56(11):1680-1695
pubmed: 28282123

Auteurs

Ghayah Bahatheg (G)

School of Chemistry, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.
Department of Chemistry, Faculty of Science, University of Jeddah, Jeddah 21589, Saudi Arabia.

Rajesh Kuppusamy (R)

School of Chemistry, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.
School of Optometry and Vision Science, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.

Muhammad Yasir (M)

School of Optometry and Vision Science, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.

David StC Black (DS)

School of Chemistry, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.

Mark Willcox (M)

School of Optometry and Vision Science, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.

Naresh Kumar (N)

School of Chemistry, The University of New South Wales (UNSW), Sydney, NSW 2052, Australia.

Classifications MeSH